Pituitary/growth disorders
NEWS
Genetic testing has identified a likely cause for nonfamilial tall stature in 11% of children examined, show study findings published in the European Journal of Pediatrics.
Research from the Netherlands suggests that the majority of children heterozygous for pathogenic alterations to the NPR2 gene, resulting in mild skeletal dysplasia, respond to growth hormone therapy.
The European Society for Paediatric Endocrinology (ESPE) has released a position statement to encourage further research into endocrine immune-related adverse events associated with the use of immune checkpoint inhibitors in children with cancer.
For teenage boys with idiopathic short stature (ISS), combining a third-generation aromatase inhibitor with recombinant human growth hormone therapy can significantly improve adult height, suggest study findings published in the Journal of Clinical Endocrinology & Metabolism.
In depth
We are excited to welcome you to the Insights into MAnaging Growth for Endocrine nurses (IMAGE) June 2025 Meeting, organised by Springer Healthcare IME. This event will take place on 5–6 June 2025 in the vibrant city of Lisbon in Portugal.
In our latest expert review, Afiya Andrews outlines the broad phenotypic spectrum of classical and non-classical growth hormone insensitivity disorders in children.
A 12-year-old boy with a diagnosis of Carney Complex (CC) has accelerated growth. How does the endocrinologist manage this patient?
The Insights into MAnaging Growth for Endocrine nurses (IMAGE) March 2024 Meeting, organised by Springer Healthcare IME, provides high-quality, practical clinical training for nurses involved in paediatric endocrinology practice.
